exhibit 
exhibit {num} 
globus medical completes acquisition of alphatec's 
international business 
audubon , pa , september {num} {num} : globus medical , inc . ( nyse : gmed ) , a leading musculoskeletal implant manufacturer , today announced that it has successfully completed the previously announced acquisition of the international operations and distribution channels of alphatec holdings , inc . , a publicly traded medical devices company ( nasdaq : atec ) . 
david paul , chairman and ceo said , " we were able to close this transaction ahead of schedule thanks to the hard work and cooperation of both companies involved . strategically , this acquisition gives us immediate access to japan and increased presence and penetration in other key geographies , and significant scale , roughly doubling our international sales . in addition , we will be acquiring a talent pool of international sales professionals as well as an extensive network of international distributors . we remain excited about the future growth potential of our international business as a result of this transaction . " 
as a result of the acquisition , globus medical will assume alphatec's existing international direct and distributor sales channels . globus medical intends to offer its own products through these sales channels , but during the transition , globus medical will continue to sell alphatec products . the transaction includes a supply agreement through which alphatec will supply its products to globus medical for up to five years . 
about globus medical , inc . 
globus medical , inc . is a leading musculoskeletal implant company based in audubon , pa . the company was founded in {num} by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders . 
non-gaap financial measures 
to supplement our financial statements prepared in accordance with u . s . generally accepted accounting principles ( " u . s . gaap " ) , management uses certain non-gaap financial measures . for example , non-gaap diluted earnings per share represents diluted earnings per share excluding the provision for litigation , acquisition related items , and adjusted for the tax effects of such adjustments . we believe this non-gaap measure is a useful indicator of our operating performance , and particularly as an additional measure of comparative operating performance from period to period as it removes the effects of litigation and acquisition related items , which we believe are not reflective of underlying business trends . 
non-gaap diluted earnings per share is not calculated in conformity with u . s . gaap . non-gaap financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with u . s . gaap . these measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results . our definition of non-gaap diluted earnings per share may differ from that of other companies and therefore may not be comparable . 
safe harbor statements 
all statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as " believe , " " may , " " might , " " could , " " will , " " aim , " " estimate , " " continue , " " anticipate , " " intend , " " expect , " " plan " and other similar terms . these forward-looking statements are based on our current assumptions , expectations and estimates of future events and trends . forward-looking statements are only predictions and are subject to many risks , uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted . these risks and uncertainties include , but are not limited to , factors affecting our quarterly results , our ability to manage our growth , our ability to sustain our profitability , demand for our products , our ability to compete successfully ( including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel ) , our ability to rapidly 
develop and introduce new products , our ability to develop and execute on successful business strategies , our ability to successfully integrate the international operations acquired from alphatec , both in general and on our anticipated timeline , our ability to transition alphatec's international customers to globus medical products , our ability to realize the expected benefits to our results from the alphatec acquisition , our ability to comply with laws and regulations that are or may become applicable to our businesses , our ability to safeguard our intellectual property , our success in defending legal proceedings brought against us , trends in the medical device industry , general economic conditions , and other risks . for a discussion of these and other risks , uncertainties and other factors that could affect our results , you should refer to the disclosure contained in our most recent annual report on form {num}-k filed with the securities and exchange commission , including the sections labeled " risk factors " and " cautionary note concerning forward-looking statements , " and in our forms {num}-q , forms 8-k and other filings with the securities and exchange commission . these documents are available at www . sec . gov . moreover , we operate in an evolving environment . new risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties , nor can we assess the impact of all factors on our business or the extent to which any factor , or combination of factors , may cause actual results to differ materially from those contained in any forward-looking statements . given these risks and uncertainties , readers are cautioned not to place undue reliance on any forward-looking statements . forward-looking statements contained in this press release speak only as of the date of this press release . we undertake no obligation to update any forward-looking statements as a result of new information , events or circumstances or other factors arising or coming to our attention after the date hereof . 
contact : 
daniel scavilla 
senior vice president , chief financial officer 
phone : ( {num} ) {num}-{num} 
email : investors@globusmedical . com 
www . globusmedical . com 
